Actively Recruiting
CEDRN: Opioid Registry
Led by University of British Columbia · Updated on 2026-03-12
7200
Participants Needed
1
Research Sites
283 weeks
Total Duration
On this page
Sponsors
U
University of British Columbia
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Unregulated opioids remain a leading driver of preventable mortality and potential years of life lost in Canada. Emergency departments (EDs)-open 24/7 and frequently accessed by people who use drugs-offer critical opportunities to reverse toxicity, mitigate harm, and initiate treatment. Yet, high quality evidence to guide ED care for patients with opioid poisoning and concomitant opioid dependence or opioid use disorder is limited. The investigators aim to establish a pan Canadian registry of patients presenting to EDs with opioid poisoning to generate timely, practice informing evidence. The investigators will create the Canadian Emergency Department Research Network (CEDRN) Opioid Registry across participating EDs nationwide. Using automated screening of electronic health records (EHRs), the investigators will identify consecutive patients of all ages with suspected or confirmed opioid poisoning at their index ED visit. The project's objectives are to establish a pan-Canadian registry of Emergency Department patients presenting with opioid poisoning, harmonize data collection across participating sites, describe variations in patient characteristics, clinical practice and outcomes, and derive a clinical decision rule to predict the risk of dying within 60 days. The expected outcomes include advancing healthcare delivery, improving patient and provider experiences, and enhancing population health and health system sustainability for individuals with opioid poisoning. This research is crucial for addressing the opioid crisis in Canada and has the potential to significantly impact patient care and outcomes.
CONDITIONS
Official Title
CEDRN: Opioid Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who arrive at the emergency department with discharge diagnoses of overdose or intoxication from Percocet, Oxycontin, Oxycodone, Methadone, Heroin, Fentanyl, Codeine, Carfentanil, or opioid withdrawal
- Patients who have had medications ordered during the present or past two years' hospital visits including Buprenorphine, Buprenorphine-naloxone, Methadone, Kadian/Morphine long-acting, Naloxone, or Naloxone kit
- Patients with inpatient discharge diagnoses of opioid use disorder (mild, moderate, or severe), opioid-related disorders, adverse effects or poisoning by polysubstance use, opioid intoxication or withdrawal, intoxication or withdrawal from any substance, adverse effects or poisoning by opioids, benzodiazepines, antiepileptic or sedative-hypnotic drugs, or any psychoactive substance abuse resulting in intoxication, withdrawal, or adverse effects
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Actively Recruiting
Research Team
J
Jeffrey P Hau, MSc
CONTACT
V
Vi Ho, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here